IP Library › Granted Patent US 7,112,342
Granted Patent B2
US 7,112,342 · App. 10/356,145 · Granted Sep 26, 2006

Enriched platelet wound healant

Assignee: Cytomedix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,112,342
App. No.
10/356,145
Granted
Sep 26, 2006
Kind
B2
Abstract

An improved platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises a therapeutically effective amount of activated growth factors and ascorbic acid with optional one or more additional anti-oxidant such as vitamin A and/or E, and optional one or more antibiotics.

Claims (12)

1. A method of treating a wound in a patient comprising the steps of applying to a wound a composition comprising a therapeutically effective amount of an activated platelet concentrate in combination with an effective gelation prolonging amount of ascorbic acid in an amount ranging between about 20 mg and about 65 mg/ml of platelet concentrate.

2. The method according to claim 1 , wherein said activation of said platelets results from the inclusion of an agonist.

3. The method according to claim 2 , wherein said agonist is selected from the group consisting of thrombin, collagen serotonin, ADP and acetylcholine (ACH), and combinations thereof.

4. The method according to claim 2 , wherein said activation of said platelets results from the inclusion of thrombin.

5. The method according to claim 1 , wherein said platelet concentrate is autologous.

6. The method according to claim 1 , wherein said composition further comprises at least one retinoid.

7. The method according to claim 6 , wherein said retinoid is vitamin A.

8. The method according to claim 1 , wherein said composition further comprises vitamin E.

9. The method according to claim 2 , wherein said composition further comprises at least one antibiotic.

10. The method according to claim 9 , wherein said antibiotic is bacteriocidal to at least Pseudomonas and Klebsella bacteria.

11. The method according to claim 9 , wherein said antibiotic is selected from the group consisting of a neosporin, vancomycin and gentamycin, and combinations thereof.

12. The method according to claim 1 , wherein said wound healant composition further comprises at least one retinoid and at least one antibiotic which is bacteriocidal to Pseudomonas and Klebsella bacteria.

Assignments (5)
CHANGE OF NAME Recorded Feb 4, 2015
From: CYTOMEDIX, INC.
To: NUO THERAPEUTICS, INC.
Reel/Frame 034890/0806 →
RELEASE OF SECURITY INTEREST Recorded Apr 16, 2014
From: MIDCAP FUNDING III, LLC, AS AGENT
To: CYTOMEDIX, INC.; CYTOMEDIX ACQUISITION COMPANY, LLC; ALDAGEN, INC.
Reel/Frame 032684/0950 →
SECURITY INTEREST Recorded Apr 8, 2014
From: CYTOMEDIX, INC.; ALDAGEN, INC.; CYTOMEDIX ACQUISITION COMPANY, LLC
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; DEERFIELD SPECIAL SITUATIONS FUND, L.P.; DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.; DEERFIELD MGMT, L.P., AS AGENT
Reel/Frame 032629/0109 →
SECURITY AGREEMENT Recorded Feb 21, 2013
From: CYTOMEDIX, INC.; CYTOMEDIX ACQUISITION COMPANY, LLC; ALDAGEN, INC.
To: MIDCAP FUNDING III, LLC
Reel/Frame 029854/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2012
From: WORDEN, CHARLES E.
To: CYTOMEDIX, INC.
Reel/Frame 029240/0584 →
Continuity (6)
Division 0977092400 · Jan 26, 2001
Continuation In Part 0942452300 · Nov 23, 1999
Continuation In Part PCTUS990298100 · Feb 13, 1999
Provisional Application 6009789700 · Aug 26, 1998
Provisional Application 6009016700 · Jun 22, 1998
Related Publication 20040001816A1 · Jan 1, 2004